EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs ...Middle East

PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop...

Hence then, the article about epivax and cubrc awarded fda contract worth 2m for development of control peptides for immunogenicity risk assessment assays supporting regulatory filings of generic peptide drugs was published today ( Thursday 24/10/2024 - 04:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs )

Also on site :

• Gunman opens fire and seizes supermarket in Kiev (VIDEOS)
• Three Papers Published Consecutively in Nature Energy: JinkoSolar's Breakthroughs in TOPCon/Perovskite Tandem Technology Receive Authoritative Recognition
• Trump rolls out Joe Rogan for White House psychedelics announcement and jokes he’d like some for anxiety